Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Wyeth announces positive results from Phase III psoriasis study
During the 48-week study, the standard Psoriasis Area and Severity Index (PASI 75) was used to evaluate the efficacy of Enbrel in patients between 4 and 17 years
During the 48-week study, the standard Psoriasis Area and Severity Index (PASI 75) was used to evaluate the efficacy of Enbrel in patients between 4 and 17 years
The crossover study (CG106) will characterize the pharmacodynamic effects of CGT-2168 compared with Plavix and will expand earlier findings of comparability. Separately, Cogentus has begun Cogent-1, a global
Rhei Pharmaceuticals will be responsible for marketing MuGard in China, Hong Kong, Macau, Taiwan, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand and Vietnam, as well as
One of the studies, designated the ‘SUPPORT’ study, will assess the efficacy and safety of Cerimon’s patch compared to placebo for the treatment of pain due to acute
Under this agreement, Pfizer will obtain a worldwide exclusive license to develop and commercialize CD-RAP. In addition to receiving royalties on the sale of any products that may
The decision of the FDA allows the product to be sold in the US, where it is patent protected until 2017. Nycomed is in active negotiations with possible
The Phase I clinical trials are open-label, dose escalation studies of SGX523 administered orally to patients with advanced cancer who have either failed standard therapy or for whom
By promoting the development, coordination and sharing of research resources and expertise, these awards expand research opportunities and increase the number of competitive investigators in 23 eligible states
Two new fully segregated state-of-the-art viral product manufacturing suites will be built to employ the latest in disposable bioreactor technologies and enable SAFC Pharma’s viral manufacturing to increase
The new investment will support further development of Pervasis’s innovative Vascugel blood vessel repair therapeutic, presently in two Phase II clinical trials, as well as continuing research into